Health AI Central
Peer-Reviewed Publication
Cancers (Basel)2026;18(11)May 22, 2026Journal Article

Divergent Genomic Drivers in Benign-Appearing Lung Precursors and Their Synchronous Carcinomas.

Jieun Lee1, Yuchae Jung2, Seung Yun Lee1, Ye Won Song3, Jongsun Jung4, Chan Kwon Park5, Young Jo Sa6, Tae-Jung Kim1
1Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea.
2Department of Artificial Intelligence Convergence & Engineering, Open Cyber University of Korea, Seoul 02087, Republic of Korea.
3College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
4Syntekabio, Genome Data Integration Center, 519, Techno World 2, No. 187, Yuseong-gu, Daejeon 34025, Republic of Korea.
5Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Republic of Korea.
6Department of Thoracic Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Republic of Korea.
PubMed PMC DOI PDF

Abstract

BACKGROUND/OBJECTIVES: How the histologically benign tier of lung preinvasive lesions-atypical adenomatous hyperplasia (AAH) and squamous dysplasia (SD)-relates genomically to its paired carcinoma is unclear. To identify early versus late events, we compared synchronous preinvasive and invasive lesions from the same patient. METHODS: Whole-exome sequencing was performed on 33 FFPE samples from 11…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.